Gilead Sciences, Inc. (NASDAQ:GILD) Stake Increased by Corient Private Wealth LLC

Corient Private Wealth LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.2% during the fourth quarter, HoldingsChannel reports. The fund owned 632,803 shares of the biopharmaceutical company’s stock after acquiring an additional 1,163 shares during the quarter. Corient Private Wealth LLC’s holdings in Gilead Sciences were worth $58,452,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences during the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC increased its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,503,250. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of research reports. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, Oppenheimer increased their price target on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $104.52.

Gilead Sciences Stock Down 1.7 %

GILD opened at $111.44 on Monday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market capitalization of $138.78 billion, a PE ratio of 301.19, a P/E/G ratio of 0.71 and a beta of 0.21. The stock’s fifty day moving average is $101.82 and its 200-day moving average is $92.92. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.84%. Gilead Sciences’s payout ratio is 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.